ANTIBODIES TO LIPOPOLYSACCHARIDE

被引:60
作者
POXTON, IR
机构
[1] Department of Medical Microbiology, University of Edinburgh Medical School, Edinburgh, EH8 9AG Scotland, Teviot Place
关键词
ENDOTOXIN; LIPOPOLYSACCHARIDE; IMMUNOTHERAPY; ENDOTOXEMIA; SEPSIS; ANTIBODY;
D O I
10.1016/0022-1759(95)00123-R
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Lipopolysaccharides (LPS) are indispensable structural components of the Gram-negative bacterial outer membrane and are major determinants of virulence in pathogenic species. In the infected host LPS is better known as endotoxin where it acts as a potent stimulator of the inflammatory response. This article reviews the methods for the production and measurement of anti-LPS antibodies, and then describes the uses to which these methods have been employed. Antibodies to LPS (either monoclonal or polyclonal) may be used directly as immunotherapeutic agents for the treatment of Gram-negative sepsis or endotoxaemia, or as probes for the diagnosis and epidemiological investigation of Gram-negative bacterial infections. Antibodies are useful tools for investigation of the chemical structure of LPS, its expression on bacteria and to study the role of LPS in pathogenic mechanisms. The detection and quantitation of anti-LPS antibodies has formed the basis of classical and more recent serological studies of major bacterial infections.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 85 条
[1]   ANTI-BACTEROIDES LIPOPOLYSACCHARIDE IGG LEVELS IN HEALTHY-ADULTS AND SEPSIS PATIENTS [J].
ALLAN, E ;
POXTON, IR ;
BARCLAY, GR .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 1995, 11 (01) :5-12
[2]  
APPELMELK BJ, 1987, FEMS MICROBIOL LETT, V40, P71
[3]   ANTIGENIC AND IMMUNOGENIC DIFFERENCES IN LIPOPOLYSACCHARIDES OF ESCHERICHIA-COLI J5 VACCINE STRAINS OF DIFFERENT ORIGINS [J].
APPELMELK, BJ ;
MAASKANT, JJ ;
VERWEIJVANVUGHT, AMJJ ;
VANDERMEER, NM ;
THIJS, BG ;
MACLAREN, DM .
JOURNAL OF GENERAL MICROBIOLOGY, 1993, 139 :2641-2647
[4]   CROSS-REACTIVITY OF MONOCLONAL-ANTIBODIES TO ESCHERICHIA-COLI J5 WITH HETEROLOGOUS GRAM-NEGATIVE BACTERIA AND EXTRACTED LIPOPOLYSACCHARIDES [J].
AYDINTUG, MK ;
INZANA, TJ ;
LETONJA, T ;
DAVIS, WC ;
CORBEIL, LB .
JOURNAL OF INFECTIOUS DISEASES, 1989, 160 (05) :846-857
[6]  
BARCLAY GR, 1989, CIRC SHOCK, V29, P93
[7]  
Barclay GR., 1990, REV MED MICROBIOL, V1, P133
[8]  
Baumgartner J. D., 1994, Reviews in Medical Microbiology, V5, P183
[9]   ANTIBODIES TO LIPOPOLYSACCHARIDES AFTER IMMUNIZATION OF HUMANS WITH THE ROUGH MUTANT ESCHERICHIA-COLI J5 [J].
BAUMGARTNER, JD ;
HEUMANN, D ;
CALANDRA, T ;
GLAUSER, MP .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (04) :769-772
[10]   AFFINITY-PURIFIED ESCHERICHIA-COLI J5 LIPOPOLYSACCHARIDE-SPECIFIC IGG PROTECTS NEUTROPENIC RATS AGAINST GRAM-NEGATIVE BACTERIAL SEPSIS [J].
BHATTACHARJEE, AK ;
OPAL, SM ;
PALARDY, JE ;
DRABICK, JJ ;
COLLINS, H ;
TAYLOR, R ;
COTTON, A ;
CROSS, AS .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (03) :622-629